Can-Fite BioPharma Ltd.
CANF
$3.39
$0.030.89%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.30% | -43.30% | -36.08% | -36.08% | 15.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.30% | -43.30% | -36.08% | -36.08% | 15.48% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -43.30% | -43.30% | -36.08% | -36.08% | 15.48% |
| SG&A Expenses | 4.86% | 4.86% | 35.48% | 35.48% | 5.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.59% | 19.59% | 15.65% | 15.65% | 10.46% |
| Operating Income | -25.17% | -25.17% | -19.64% | -19.64% | -10.03% |
| Income Before Tax | -26.23% | -26.23% | -23.22% | -23.22% | -18.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.23% | -26.23% | -23.22% | -23.22% | -18.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.23% | -26.23% | -23.22% | -23.22% | -18.73% |
| EBIT | -25.17% | -25.17% | -19.64% | -19.64% | -10.03% |
| EBITDA | -25.33% | -25.33% | -19.11% | -19.11% | -10.09% |
| EPS Basic | 50.59% | 50.59% | 34.22% | 34.22% | 30.37% |
| Normalized Basic EPS | 50.46% | 50.46% | 34.22% | 34.22% | 31.08% |
| EPS Diluted | 50.59% | 50.59% | 34.22% | 34.22% | 30.37% |
| Normalized Diluted EPS | 50.46% | 50.46% | 34.22% | 34.22% | 31.08% |
| Average Basic Shares Outstanding | 155.49% | 155.49% | 87.33% | 87.33% | 70.54% |
| Average Diluted Shares Outstanding | 155.49% | 155.49% | 87.33% | 87.33% | 70.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |